The EbolaVac consortium is composed of four European partners (GSK, The University of Oxford, The Bernhard Nocht Institute for Tropical Medicine and The Hospices Cantonaux / University Hospital of Lausanne) recognised for their excellence and capacity to design, organise and execute clinical programmes.

The websites listed on this page (except for GSK's website) are external to GSK and are for general information purposes only.

GSK makes no claims or warranties as to the accuracy, completeness or use of the information provided on these external websites.

EbolaVac gathers a network of researchers with internationally recognised expertise and experience in infectious diseases, clinical studies, epidemiology and vaccinology. One multinational company (GSK) will ensure the full exploitation of the generated output and knowledge. The four participants have a proven and productive background in Europe and Africa in the conduct of clinically-driven experimental research in emerging infections, immunology, clinical trials and product development and commercialisation.

Partner 1- GlaxoSmithKline Vaccines, Belgium (GSK)

GSK is responsible for the coordination of the consortium and has recognised expertise in all aspects of vaccine development. GSK Vaccines will also be responsible for managing the Phase II studies, acting as the sponsor.

GSK owns the chimpanzee Adenovirus (ChAd) platform acquired from Okairos in 2013, and in-licensed some of the intellectual property underlying the candidate EbolaVirus vaccine developed in partnership with VRC/NIAID.

Partner 2- The University of Oxford, United Kingdom (UOXF)

The University of Oxford has extensive experience in vaccinology with vaccine research and development activities centred at the Jenner Institute. The Jenner Institute, University of Oxford is a research partnership between the University of Oxford and the Pirbright Institute. The Institute focuses on the parallel development of human and veterinary vaccines against major global diseases, from early-stage research through to clinical trials.

In August 2014, the Jenner Institute received a Wellcome Trust Strategic Award for the conduct of Phase I Ebola vaccine trials in Oxford, Mali and The Gambia. The first vaccination in Oxford was administered on 17th of September 2014.

If you want to find out more about this institution and the people involved in the Ebola research, please visit the University of Oxford or Jenner Institute website.

Partner 3- The Bernhard Nocht Institute for Tropical Medicine, Germany (BNITM)

The Bernhard Nocht Institute for Tropical Medicine (BNITM) is Germany’s largest institution for research, services and training in the field of tropical diseases and emerging infections.

Research topics include clinical studies, epidemiology and disease control as well as the biology of the respective pathogens, their reservoirs and vectors. The current scientific focus is on malaria, haemorraghic fever viruses, tuberculosis (TB) and tissue nematodes. To study highly pathogenic viruses and infected insects, the institute is equipped with laboratories of the highest biosafety levels (BSL4) and a BSL3 insectary.

BNITM comprises the German National Reference Centre for the diagnostics of all tropical pathogens and the WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research. Together with the Ghanaian Ministry of Health and the University of Kumasi, it runs a modern research and training centre in the West African rainforest, which is also available to external research groups.

BNITM coordinates the focus “global and emerging infections” of the German Centre for Infection Research in northern Germany and is member of the Leibniz foundation.

If you want to find out more about this institution and the people involved in the Ebola research, please visit the BNITM webpage.

Partner 4- The Hospices Cantonaux / University Hospital of Lausanne, Switzerland (CHUV)

The Hospices Cantonaux / University Hospital of Lausanne (CHUV, in French: Centre Hospitalier Universitaire Vaudois), in Lausanne, is one of the five university hospitals in Switzerland.

The Hospices Cantonaux CHUV are linked to the Faculty of Biology and Medicine of the University of Lausanne (UNIL). It is a 1000-bed hospital that serves the population of the Canton de Vaud and surroundings (~1 million inhabitants). It has a Clinical Trial Unit (CTU Lausanne) that allows conducting Phase I-III trials at highest standards with excellent efficiency. CTU Lausanne is part of the Swiss Clinical Trial Organization.

The CHUV has been conducting many vaccine trials, especially for malaria, human immunodeficiency virus (HIV) and TB. This is the reason why the World Health Organization has contacted Prof. Blaise Genton, who is a leader in running clinical trials both in Switzerland and in Africa, through his double affiliation with the Swiss Tropical and Public Health Institute. This link will ensure a smooth process from Phase I/II in Switzerland (Lausanne study) to Phase I/II in Africa and potential deployment in epidemic areas, should the vaccine demonstrate an acceptable safety profile and immune response in early trials.

The Lausanne study is part of Horizon 2020 EbolaVac project. The funding for the study comes from the Swiss government directly.

If you want to find out more about this institution and the people involved in the Ebola research, please visit the CHUV website.